335 related articles for article (PubMed ID: 21254949)
1. Ivabradine: recent and potential applications in clinical practice.
Riccioni G
Expert Opin Pharmacother; 2011 Feb; 12(3):443-50. PubMed ID: 21254949
[TBL] [Abstract][Full Text] [Related]
2. Ivabradine: beyond heart rate control.
Riccioni G; Vitulano N; D'Orazio N
Adv Ther; 2009 Jan; 26(1):12-24. PubMed ID: 19165437
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
[TBL] [Abstract][Full Text] [Related]
4. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
Canet E; Lerebours G; Vilaine JP
Ann N Y Acad Sci; 2011 Mar; 1222():90-9. PubMed ID: 21434947
[TBL] [Abstract][Full Text] [Related]
5. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
Bruguera Cortada J; Varela A
Am J Cardiovasc Drugs; 2009; 9 Suppl 1():9-12. PubMed ID: 20000882
[TBL] [Abstract][Full Text] [Related]
6. Heart rate in ischemic heart disease. The innovation of ivabradine: more than pure heart rate reduction.
Rosano GM; Vitale C; Volterrani M
Adv Ther; 2010 Apr; 27(4):202-10. PubMed ID: 20495895
[TBL] [Abstract][Full Text] [Related]
7. Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial.
Danchin N
Therapie; 2009; 64(2):111-4. PubMed ID: 19664404
[TBL] [Abstract][Full Text] [Related]
8. Rate control with ivabradine: angina pectoris and beyond.
Parakh N; Bhargava B
Am J Cardiovasc Drugs; 2011; 11(1):1-12. PubMed ID: 21090826
[TBL] [Abstract][Full Text] [Related]
9. The importance of reducing heart rate in cardiovascular diseases: effects of Ivabradine.
Vizzardi E; Bonadei I; D'Aloia A; Del Magro F; Piovanelli B; Bontempi L; Curnis A; Dei Cas L
Minerva Med; 2011 Oct; 102(5):373-9. PubMed ID: 22193347
[TBL] [Abstract][Full Text] [Related]
10. Resting heart rate in cardiovascular disease.
Fox K; Borer JS; Camm AJ; Danchin N; Ferrari R; Lopez Sendon JL; Steg PG; Tardif JC; Tavazzi L; Tendera M;
J Am Coll Cardiol; 2007 Aug; 50(9):823-30. PubMed ID: 17719466
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor.
Borer JS; Le Heuzey JY
Am J Ther; 2008; 15(5):461-73. PubMed ID: 18806523
[TBL] [Abstract][Full Text] [Related]
12. Ivabradine: I(f) inhibition in the management of stable angina pectoris and other cardiovascular diseases.
Tardif JC
Drugs Today (Barc); 2008 Mar; 44(3):171-81. PubMed ID: 18536779
[TBL] [Abstract][Full Text] [Related]
13. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
Fox K; Ford I; Steg PG; Tendera M; Robertson M; Ferrari R;
Eur Heart J; 2009 Oct; 30(19):2337-45. PubMed ID: 19720635
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effect of ivabradine against cardiovascular diseases.
Gammone MA; Riccioni G; Massari F; D'Orazio N
Front Biosci (Schol Ed); 2020 Mar; 12(1):161-172. PubMed ID: 32114453
[TBL] [Abstract][Full Text] [Related]
15. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).
Tendera M; Talajic M; Robertson M; Tardif JC; Ferrari R; Ford I; Steg PG; Fox K;
Am J Cardiol; 2011 Mar; 107(6):805-11. PubMed ID: 21247517
[TBL] [Abstract][Full Text] [Related]
16. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
Fox K; Ford I; Steg PG; Tendera M; Ferrari R;
Lancet; 2008 Sep; 372(9641):807-16. PubMed ID: 18757088
[TBL] [Abstract][Full Text] [Related]
17. Ivabradine -- the first selective sinus node I(f) channel inhibitor in the treatment of stable angina.
Sulfi S; Timmis AD
Int J Clin Pract; 2006 Feb; 60(2):222-8. PubMed ID: 16451297
[TBL] [Abstract][Full Text] [Related]
18. Heart rate as a treatable cardiovascular risk factor.
Tardif JC
Br Med Bull; 2009; 90():71-84. PubMed ID: 19474056
[TBL] [Abstract][Full Text] [Related]
19. Ivabradine: pharmacodynamic aspects of its clinical use.
Stieber J
Methods Find Exp Clin Pharmacol; 2008 Oct; 30(8):633-41. PubMed ID: 19088948
[TBL] [Abstract][Full Text] [Related]
20. Heart rate in coronary syndromes and heart failure.
Orso F; Baldasseroni S; Maggioni AP
Prog Cardiovasc Dis; 2009; 52(1):38-45. PubMed ID: 19615492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
